Edopain300 mg

Edopain is a nonsteroidal anti-inflammatory drug (NSAID) that is FDA-approved for the following indications:

• Osteoarthritis (OA): Relief of the signs and symptoms of osteoarthritis, for both acute flares and long-term management.
• Rheumatoid arthritis (RA): Relief of the signs and symptoms of rheumatoid arthritis.
• Acute pain management: Management of mild to moderate acute pain in adults (e.g., post-surgical or musculoskeletal pain).

These are established, FDA-approved uses. Edopain is not indicated for use in children for these conditions, and pediatric osteoarthritis/rheumatoid arthritis use in patients under 18 has not been demonstrated as safe and effective for this drug.

Each Etodolac capsule/tablet contains Etodolac as the active pharmaceutical ingredient, commonly available in strengths of 200 mg, 300 mg, 400 mg, and 500 mg, as immediate-release capsules/tablets or extended-release tablets. Inactive ingredients (fillers, binders, coating agents) vary by manufacturer and formulation.

Edopain is a member of the pyranocarboxylic acid class of nonsteroidal anti-inflammatory drugs (NSAIDs). It possesses analgesic, anti-inflammatory, and antipyretic properties and is used for the relief of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and acute pain conditions. Like other NSAIDs, Edopain works primarily by inhibiting the cyclooxygenase (COX) enzymes involved in prostaglandin synthesis.

Edopain is available in immediate-release and extended-release oral formulations. It has been used clinically for decades and carries the same class-wide boxed warnings as other NSAIDs regarding cardiovascular and gastrointestinal risk.

Edopain belongs to the therapeutic class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), specifically the pyranocarboxylic acid chemical subclass. It is used as an analgesic, anti-inflammatory, and antipyretic agent.

Mechanism of action: Etodolac exerts its anti-inflammatory, analgesic, and antipyretic effects primarily through inhibition of cyclooxygenase (COX) enzymes, which reduces the synthesis of prostaglandins from arachidonic acid. Prostaglandins mediate inflammation, pain, and fever, so their reduction underlies the therapeutic effects of Etodolac.

Etodolac shows some relative selectivity for COX-2 over COX-1 compared with certain older NSAIDs at therapeutic doses, though it is not a selective COX-2 inhibitor and still carries the class-wide gastrointestinal and cardiovascular risks of NSAIDs.

Pharmacokinetics: Etodolac is well absorbed orally, is highly protein bound (>99%), undergoes hepatic metabolism, and is eliminated mainly via the kidneys as metabolites. Its elimination half-life is approximately 6-8 hours (immediate release), supporting its use in both immediate-release (twice or three times daily) and extended-release (once daily) formulations.

Edopain is administered orally. Immediate-release capsules/tablets may be taken with or without food, though taking with food, milk, or an antacid may reduce gastrointestinal upset. Extended-release tablets should be swallowed whole with a full glass of water and must not be crushed, chewed, or split, as this could result in rapid release of a dose intended to be released slowly.

Edopain has several clinically significant drug interactions:

• Aspirin and other NSAIDs: Concurrent use increases the risk of GI bleeding/ulceration without improving efficacy; avoid combining Edopain with other NSAIDs or aspirin (except low-dose aspirin for cardioprotection, used cautiously).
• Anticoagulants (e.g., warfarin) and antiplatelet agents: Edopain can potentiate anticoagulant effects and increase bleeding risk; monitor INR/coagulation closely if co-administered.
• ACE inhibitors, angiotensin receptor blockers (ARBs), and diuretics: Edopain may reduce the antihypertensive and diuretic effects of these agents and increase the risk of acute kidney injury, particularly in volume-depleted patients (the "triple whammy" effect when combined with a diuretic and ACE inhibitor/ARB).
• Lithium: Edopain can reduce renal clearance of lithium, leading to elevated lithium levels and toxicity; monitor lithium levels if co-administered.
• Methotrexate: Edopain may decrease methotrexate clearance, increasing the risk of methotrexate toxicity, particularly at higher methotrexate doses.
• Corticosteroids: Concomitant use with Edopain increases the risk of GI ulceration and bleeding.
• Cyclosporine: Edopain may increase the nephrotoxic potential of cyclosporine.

Common side effects of Edopain include:

• Gastrointestinal: dyspepsia, abdominal pain, nausea, diarrhea, constipation, flatulence
• Central nervous system: headache, dizziness, drowsiness
• Other: fluid retention/edema, rash, pruritus, tinnitus

Serious but less common adverse effects include gastrointestinal ulceration/bleeding/perforation, cardiovascular thrombotic events (myocardial infarction, stroke), hepatotoxicity, renal impairment, hypertension, heart failure exacerbation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), and anaphylactoid reactions. Patients should seek prompt medical attention for signs of GI bleeding (black stools, vomiting blood), chest pain, shortness of breath, sudden weakness, or slurred speech while taking Edopain.

Pregnancy: Edopain should be avoided in pregnancy starting at 20 weeks gestation because NSAID use at this stage can cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Use of Edopain is contraindicated in the third trimester due to the risk of premature closure of the fetal ductus arteriosus and possible fetal cardiac/pulmonary effects. In early pregnancy, Edopain should be used only if the potential benefit justifies the potential risk to the fetus, and only under the guidance of a physician.

Lactation: It is not well established whether Edopain passes into breast milk. Because of the potential for serious adverse reactions in a nursing infant, a decision should be made whether to discontinue nursing or discontinue Edopain, taking into account the importance of the drug to the mother, in consultation with a physician.

Edopain carries the same boxed warnings as other NSAIDs:

• Cardiovascular risk: NSAIDs including Edopain may increase the risk of serious cardiovascular thrombotic events including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and may be higher in patients with existing cardiovascular disease or risk factors. Edopain is contraindicated for perioperative pain in the setting of CABG surgery.
• Gastrointestinal risk: NSAIDs including Edopain increase the risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use, without warning symptoms, and elderly patients are at greater risk.

Additional precautions: use with caution in patients with a history of peptic ulcer disease or GI bleeding, renal or hepatic impairment, heart failure, hypertension, or fluid retention; use with caution in the elderly and in dehydrated patients; avoid combination with other NSAIDs, aspirin, anticoagulants, or corticosteroids where possible (see Drug Interactions). Edopain may mask signs of infection (fever, pain) due to its anti-inflammatory and antipyretic effects. Use the lowest effective dose for the shortest duration necessary.

Symptoms of Edopain overdose may include lethargy, drowsiness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, hypertension, acute renal failure, respiratory depression, and rarely coma or seizures. There is no specific antidote for Edopain overdose. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and symptomatic; do not attempt home treatment for a suspected overdose of Edopain.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Elderly patients are at greater risk for NSAID-associated serious GI, cardiovascular, and renal adverse events with Edopain; use the lowest effective dose and monitor closely.

Renal impairment: Edopain has not been extensively studied in patients with significant renal impairment; use with caution and monitor renal function, as NSAIDs can further reduce renal blood flow. Avoid use in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.

Hepatic impairment: Use Edopain with caution in patients with hepatic impairment; monitor liver function, as NSAIDs including Edopain have been associated with elevations of liver enzymes and rare severe hepatic reactions.

Pediatric use: Safety and effectiveness of Edopain in pediatric patients have not been established; it is not recommended for use in children.

Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of Edopain therapy depends on the indication. For acute pain, treatment is typically limited to a few days as needed. For chronic conditions such as osteoarthritis or rheumatoid arthritis, treatment may be longer-term, but the lowest effective dose should be used for the shortest duration consistent with individual treatment goals, given the cardiovascular and gastrointestinal risks that increase with prolonged NSAID use. Periodic reassessment by a physician is recommended for long-term use of Edopain.

Etodolac belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, specifically the pyranocarboxylic acid chemical subgroup of NSAIDs.

Etodolac inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the biosynthesis of prostaglandins that mediate pain, inflammation, and fever. This leads to the analgesic, anti-inflammatory, and antipyretic effects of Etodolac.

The safety and effectiveness of Edopain in pediatric patients (below 18 years of age) have not been established for its approved adult indications (osteoarthritis, rheumatoid arthritis, acute pain). Edopain is therefore not recommended for use in children, and alternative NSAIDs with established pediatric safety data and dosing should be considered if an NSAID is needed in a pediatric patient, under medical supervision.